In an interview with Pharmacy Times about her presentation at the North American Neuroendocrine Tumor Society (NANETS) 2021 neuroendocrine tumor (NET) Medical Symposium, Mei Ka Fong, PharmD, BCOP, said sunitinib was the first targeted therapy for NETs, although other targeted agents are being investigated.

Fong said other agents, such as surufatinib, have petitioned for FDA approval, so experts are awaiting those results. Several other targeted agents are in the pipeline, and they could be particularly useful for patients who have progressed while on somatostatin analogues.